460results about How to "Increase contractility" patented technology

The above-described methods and apparatus are believed to be of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants as described herein and including those known to those of skill in the art to which the invention is directed. It will understood that the present invention offers the possibility of monitoring and therapy of a wide variety of acute and chronic cardiac dysfunctions. The current invention provides systems and methods for delivering therapy for cardiac hemodynamic dysfunction.

An implantable stimulator and monitor measures a group of heart failure parameters indicative of the state of heart failure employing EGM signals, measures of blood pressure including absolute pressure P, developed pressure (DP=systolic P-diastolic P), and / or dP / dt, and measures of heart chamber volume (V) over one or more cardiac cycles. These parameters include: (1) relaxation or contraction time constant tau (.tau.); (2) mechanical restitution (MR), i.e., the mechanical response of a heart chamber to premature stimuli applied to the heart chamber; (3) recirculation fraction (RF), i.e., the rate of decay of PESP effects over a series of heart cycles; and (4) end systolic elastance (E.sub.ES), i.e., the ratios of end systolic blood pressure P to volume V. These heart failure parameters are determined periodically regardless of patient posture and activity level. The physician can determine whether a particular therapy is appropriate, prescribe the therapy for a period of time while again accumulating the stored patient data for a later review and assessment to determine whether the applied therapy is beneficial or not, thereby enabling periodic changes in therapy, if appropriate. Drug therapies and electrical stimulation therapies, including PESP stimulation, and pacing therapies including single chamber, dual chamber and multi-chamber (bi-atrial and / or bi-ventricular) pacing can be delivered. In patient's prone to malignant tachyarrhythmias, the assessment of heart failure state can be taken into account in setting parameters of detection or classification of tachyarrhythmias and the therapies that are delivered.

The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca2+ homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart failure in subjects are also disclosed. Further, the present invention provides methods which can be used to diagnose susceptibility to treatment by RNAi, and includes pharmaceutical compositions, kits and vectors including an RNAi sequence.

A heart valve stent having a section equipped to receive a heart valve implant and several proximally disposed anchoring elements, characterized by several anchoring threads, which with the one end thereof are fastened to the stent, and also with a brace fastening the anchoring threads with the other end thereof to the distal chamber wall to provide tension between the heart chamber wall and the proximally anchored anchoring elements.

A method of promoting the healing of a lesion in a smooth muscle, comprising selecting a smooth muscle portion having a lesion and applying a non-excitatory electrical field to the portion, which field reduces the mechanical activity of the portion.

A system and method for monitoring at least one chamber of a heart (e.g., a left ventricular chamber) during delivery of a refractory period stimulation (RPS) therapy to determine if the desired non-capture (i.e., lack of ventricular mechanical capture due to refractory period stimulation) occurs. The system includes an implantable or external cardiac stimulation device in association with a set of leads such as epicardial, endocardial, and / or coronary sinus leads equipped with motion sensor(s). The device receives and processes acceleration sensor signals to determine a signal characteristic indicative of chamber capture due to pacing stimulus delivery, non-capture due to RPS therapy delivery, and / or contractile status based on the qualities of evoked response to pacing stimulation.

Heavy weight stretch fabrics comprising ethylene / α-olefin interpolymer are described. The fabric often has a weight of at least 10 ounces per square yard measured according to ASTM 3776 and has a stretch of at least 10 percent measured according to ASTM D3107. These fabrics exhibit excellent chemical, resistance (for example chlorine or caustic resistance) and durability, that is they retain their shape and feel over repeated exposure to processing conditions, such as stone-washing, dye-stripping, PET-dyeing and the like, and industrial laundry conditions.

A balloon catheter is used in a closed-loop heat exchange system for manipulating the temperature of a patient. The balloon catheter is positioned in the stomach of the patient, and then expanded with a heat exchange fluid delivered through a lumen formed in the shaft of the catheter. The balloon catheter comes into contact with the wall of the stomach, and the stomach substantially conforms around the expanded balloon catheter. The heat exchange fluid is allowed to flow continuously into and out of the balloon catheter. Heat is exchanged between the balloon catheter and the stomach so as to controllably alter the temperature of at least a portion of the patient. Anti-shivering mechanisms and automatic control based on temperature feedback from the patient may be used in connection with the heat exchange system.

Apparatus (170) for heart pacing with hemodynamic improvement, including one or more electrodes (36), which convey electrical signals to respective cardiac muscle segments. Signal generation circuitry (50) applies an extended pacing signal (60, 61), having an overall duration greater than three times a chronaxie time, to the one or more electrodes so as to pace the heart. The signal preferably includes a train of a plurality of biphasic pulses, and has an amplitude at least three times as great as a threshold for pacing the heart, but not sufficient for cardioversion.

A method is provided including selecting a patient suffering from a condition, administering cells to the patient selected from the group consisting of: progenitor cells and genetically-modified cells, applying an electrical current to a site of the patient in a vicinity of nervous tissue, and configuring the current to stimulate the nervous tissue. Other embodiments are also described.

A method of producing a building panel (1), including: providing a core (2), applying a balancing layer (6) having a first moisture content on a first surface (3) of the core (2), the balancing layer (6) comprising a sheet impregnated with a thermosetting binder, applying a surface layer (12) having a second moisture content on a second surface (4) of the core (2), the surface layer (12) comprising a thermosetting binder, adjusting the first moisture content of the balancing layer (6) such that the first moisture content of the balancing layer (6) is higher than the second moisture content of the surface layer (12) prior to curing, and curing the surface layer (12) and the balancing layer (6) by applying heat and pressure. Also, a semi-finished product adapted to be cured for forming a building panel (1).

The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.

A balloon catheter is used in a closed-loop heat exchange system for manipulating the temperature of a patient. The balloon catheter is positioned in the stomach of the patient, and then expanded with a heat exchange fluid delivered through a lumen formed in the shaft of the catheter. The balloon catheter comes into contact with the wall of the stomach, and the stomach substantially conforms around the expanded balloon catheter. The heat exchange fluid is allowed to flow continuously into and out of the balloon catheter. Heat is exchanged between the balloon catheter and the stomach so as to controllably alter the temperature of at least a portion of the patient. Anti-shivering mechanisms and automatic control based on temperature feedback from the patient may be used in connection with the heat exchange system.

Apparatus (20) is provided including an inflatable bladder (40), adapted to be coupled to a blood vessel (22) of a subject (18) carrying oxygenated blood, such that an interior of the bladder (40) is in fluid communication with the blood. The apparatus also includes a piston (48) in mechanical communication with the bladder (40); a motor (60), adapted to synchronize contraction and expansion of the bladder (40) with a cardiac cycle of the subject (18) by applying a motor force to the piston (48); and a spring (54), adapted to apply a spring force to the piston (48).

A method for treating cardiac failure such as congestive heart failure by application of hypothermia. Hypothermia may be applied by endovascular cooling using a heat exchange catheter circulating heat exchange fluid between an external heat exchanger controlled using temperature feedback from a temperature probe on or in the patient to cool the heart to a sufficiently low temperature for a sufficient length of time to increase cardiac output and improve the vascular condition of the patient. The patient may be maintained in the hypothermic condition for a period of time and is then re-warmed slowly and controllably. The endovascular temperature management may be controlled automatically in response to a temperature probe on the patient, and shivering while the patient is cool may be combated using surface warming and anti-shivering drugs. The method is applicable to treat congestive heart failure and may be used repeatedly on the same patient to restore that patient to adequate heart function when the vascular condition of that patient has become unacceptable. The method may be used to maintain a patient until a heart transplant becomes available. The method may be used to stabilize a patient's condition to allow needed surgery or intervention. The method may be used in conjunction with other treatments including drugs, balloon pumps, pacing devices and ventricular assist devices.

Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin are disclosed. In particular, the invention relates to formulations comprising apelin encapsulated in liposome nanocarriers conjugated with polyethylene glycol (PEG) and their use in treatment of cardiovascular and pulmonary diseases and disorders. Encapsulation of apelin in PEG-conjugated liposomes significantly enhances efficacy, improves cellular uptake of apelin, and allows for sustained and extended release of apelin under physiological conditions.

Methods of treating or inhibiting ischemia and reperfusion injury are provided.

Apparatus (20) is provided including an inflatable bladder (40), adapted to be coupled to a blood vessel (22) of a subject (18) carrying oxygenated blood, such that an interior of the bladder (40) is in fluid communication with the blood. The apparatus also includes a piston (48) in mechanical communication with the bladder (40); a motor (60), adapted to synchronize contraction and expansion of the bladder (40) with a cardiac cycle of the subject (18) by applying a motor force to the piston (48); and a spring (54), adapted to apply a spring force to the piston (48).

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists / partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

A method is provided including selecting a patient suffering from a condition, administering cells to the patient selected from the group consisting of: progenitor cells and genetically-modified cells, applying an electrical current to a site of the patient in a vicinity of nervous tissue, and configuring the current to stimulate the nervous tissue. Other embodiments are also described.

Disclosed are hot-melt adhesives prepared from aromatic-aliphatic polyesters containing terephthalic acid in combination with adipic acid, glutaric acid, or a mixture thereof, as diacid components and a diol component containing 1,4-butanediol, 1,6-hexanediol, or a combination thereof. These adhesives set up rapidly within a well-defined temperature window. The hot-melt adhesives can be used in a variety of applications, but are especially suited as seaming adhesives for roll-applied labels. These adhesives have melting temperatures and crystallization properties that allow their application at temperatures cool enough to prevent curling and premature shrinkage of the shrink label during seaming, and yet produce strong label seams that can withstand the elevated temperatures of a shrink tunnel without sacrificing line speed. Also disclosed are labeled containers and a process for applying a roll-on, shrink label to a container using the hot-melt adhesives of the invention.

The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

A method of modifying the force of contraction of at least a portion of a heart chamber, including providing a subject having a heart, comprising at least a portion having an activation, and applying a non-excitatory electric field having a given duration, at a delay after the activation, to the portion, which causes the force of contraction to be increased by at least 5%.

A placement configuration of MIM type capacitance elements according to the present invention comprises a group of first capacitance elements in which the first capacitance elements as the MIM type capacitance elements are placed in tandem and a group of second capacitance elements in which the second capacitance elements as the MIM type capacitance elements are placed in tandem, wherein the group of first capacitance elements and the group of second capacitance elements are alternately placed in parallel with each other with an equal interval therebetween.

The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac myocytes and also to improving cardiac contractility.

Disclosed is a method for extracting dihydro quercetin from larch. The invention is an improved production method. Due to different production materials and extraction processes, the dihydro quercetin products in U.S. and European markets are very expensive, at a price of 200-1000 euros per gram. Such a high market price economically limits the wide range of practicability of dihydro quercetin products. During the pretreatment of raw materials, 50 kilograms of larch wood chips and 500-800 liters of 50% ethanol solution are added into a reactor to get fully stirred and mixed; then the mixture is extracted and filtered for the second extraction; the filtrates are combined and adsorbed; the organic solvents are collected and dried by a vacuum evaporator through organic phase vacuum distillation; according to a weight proportion of 10:1, the residues are dissolved with hot water, decolorized with activated carbon and then crystallized at a temperature of 3-5 DEG C to precipitate the dihydro quercetin product which is then crushed after vacuum drying to finished product. The invention is used to extract dihydro quercetin from larch.

Methods for curative ablation are provided to achieve the inactivation or destruction of fibrillar myocardium of the so-called AF nests. In addition, fibrillar myocardium may be identified and mapped by spectral analysis and phase study of the tissue during sinus rhythm. The procedure may be performed by transseptal puncture using only one catheter for ablation and mapping. The methods may be used to localize the application targets even during an arrhythmia.

The invention relates to a maca function beverage which comprises the following raw materials in percentage by weight: 96.5%-98.7% of purified water, 0.5%-2.0% of maca extract liquid, 0.5%-0.8% of sorbitol liquid and 0.04%-0.06% of sorbic acid. The maca function beverage is a pure natural beverage, has the effects of remarkably improving human body immunity, resisting fatigue, replenishing energy and improving human body energy, has a body building effect after being drunk for a long term, and does not have side effects. A preparation method of the maca function beverage is provided.